Business
Jenscare, with innovative TTVR and approved TAVR, releases 2024 annual results
Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with TTVR breakthroughs and is entering commercialization stage for its TAVR (AR) product, released its annual results for year ended December 31, 2024.
About this update from Jenscare Scientific Co. Ltd. Class H
[{"type":"text","content":"BEIJING, March 25, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with TTVR breakthroughs and is entering commercialization stage for its TAVR (AR) product, released its annual results for year ended December 31, 2024.","length":323,"tagName":"p"},{"type":"text","content":"Financial Highlights: Net Loss Narrowed Greatly with Sufficient Cash Balance for the Upcoming Commercialization","length":111,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net loss attributable to common shareholders was RMB 178 million[1] (US$ 25 million), narrowed down greatly by 52.2% compared to 2023.","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents, term deposits and financial assets was RMB 708 million (US$ 98 million), which remained robust and sufficient, safeguarding the commercialization of its core products and R&D efforts.","length":214,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":348,"olType":false},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.17em;","val":[{"type":"text","content":"[1] Conversions from RMB to US$ is made at an exchange rate of RMB7.2377 to US$1.00, set forth in the H.10 statistical release of the Federal Reserve Board on March 17, 2025.","length":174,"tagName":"p","attribs":{}}]}]}],"length":174},{"type":"text","content":"Business Overviews: The Global Influence of TTVR System Continues to Expand, and TAVR (AR) System has Entered Commercialization Phase","length":133,"tagName":"p"},{"type":"text","content":"The Company is committed to becoming a globally leading innovative medical device company, dedicated to meeting the huge and urgent treatment needs worldwide. In 2024, the Company further advanced the commercialization preparations for its core product, LuX-Valve Plus, on a global scale. It released significant clinical data at multiple important international academic conferences and successfully progressed the registration clinical trials in overseas regions, including the U.S., Europe and China. Another core product of the Company, Ken-Valve, obtained approval for registration from the NMPA at the beginning of 2025. The Company is actively promoting its c...